Compare Illumina, Inc. (ILMN) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Microchip Technology Inc. — how do they compare? Illumina, Inc. trades at $190.08 (market cap $27.94B), while Microchip Technology Inc. trades at $83.19 (market cap $43.72B). The key difference: Microchip Technology Inc. is the larger of the two by market cap, and Microchip Technology Inc. pays a 2.26% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | MCHP | |
|---|---|---|
Market Cap | $27.94B | $43.72B |
Sector | Health | Technology |
52-Week High | $194.33 | $102.97 |
52-Week Low | $91.00 | $49.02 |
Enterprise Value | $29.33B | $49.01B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
MCHP trades at $80.64, down 0.4% on the day, with technical indicators signaling a bearish trend. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 expected at $0.70 EPS. Revenue declined to $4.40B in 2025, resulting in a net loss, but margins are projected to recover in 2026. Positive sentiment is driven by AI and aerospace demand, with 68% of analysts rating it a Buy.
Outlook is mixed: strong analyst consensus targets $113.33, but high P/E of 368 and recent net loss pose valuation risks. Key opportunities include AI data center growth and inventory recovery, while supply chain constraints and semiconductor cycle volatility remain headwinds. The stock offers upside if earnings rebound as forecasted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
